The disclosure relates to dendritic polyglycerols (dPG) compounds with carboxyalkyl, sulfyl or sulfonyl functional groups that irreversibly inhibit viral infection (virucidal effect) through multivalent interaction in nanomolar concentration range. While the compounds of the disclosure show virus inhibition in the nanomolar range they show no in-vitro toxicity in the same range of concentration.

The disclosure relates to dendritic polyglycerols (dPG) compounds with carboxyalkyl, sulfyl or sulfonyl functional groups that irreversibly inhibit viral infection (virucidal effect) through multivalent interaction in nanomolar concentration range. While the compounds of the disclosure show virus inhibition in the nanomolar range they show no in-vitro toxicity in the same range of concentration.

A method for the treatment or amelioration of Acute Respiratory Distress Syndrome (ARDS) comprising the steps of administering to a subject a therapeutically effective amount of at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof.

A method for the treatment or amelioration of Acute Respiratory Distress Syndrome (ARDS) comprising the steps of administering to a subject a therapeutically effective amount of at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof.

A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound represented by the following Formula (I): where R.sup.1 is selected from hydrogen or an alkyl group having from 1 to about 16 carbon atoms; R.sup.2 is selected from a hydroxyl group, a tosylate group, an alkoxy group of the formula OR.sup.3 where R.sup.3 is selected from an alkyl group having from 1 to about 16 carbon atoms, or an ester group of the formula OCOR.sup.4, where R.sup.4 is an alkyl group having from 1 to about 16 carbon atoms, and n is from 4 to 46,000, with the proviso that when R.sup.1 is hydrogen and R.sup.2 is a hydroxy group the treatment compound has a number average molecular weight from 10,100 to 2,000,0000 g/mol.

##STR00001##